

RESEARCH

Open Access



Differential response to topical lubrication in patient with dry eye disease, based on age

Yingxin Chen¹, Yajun Wu¹, Minghong Gao^{1*}, Ruiyao Gao¹ and Kai Zhang¹

Abstract

Background To compare the Ocular surface disease index (OSDI) score, Schirmer I test (SIT), fluorescein break up time (FBUT) and fluorescence staining (FLCS) score of dry eye patients at different ages.

Methods 90 eyes of 90 patients with mild to moderate dry eye from September 2020 to September 2021 were retrospectively included and were divided into young group (20–39 years, n = 29), middle-age group (40–59 years, n = 30), and elder group (> 60 years, n = 31). Patients were given a 28-day topical lubricating ocular surface and repair-promoting drugs combined with local physical therapy. Patients were followed up at 7, 14 and 28 days. The OSDI score, SIT, FBUT and FLCS score were examined.

Results There were differences between the OSDI score in three groups at each time point (all $P < 0.001$). SIT were different among the three groups ($F = 350.61$, $P < 0.001$), and a time effect was found ($F = 80.87$, $P < 0.001$). SIT at 14 and 28 days after treatment in middle-age and elder groups were lower than young group (all $P < 0.001$). SIT at 7, 14 and 28 days in elder group were lower than middle-age group (all $P < 0.001$). FLCS score was lower at 28 days than other time points (all $P < 0.001$).

Conclusion Dry eye patients are given a 28-day topical lubricating ocular surface and repair-promoting drugs combined with local physical therapy, which can promote tear secretion, film stability, and the recovery of corneal integrity. Age affects the treatment effect of mild to moderate dry eye, among which tear secretion is the most significant.

Keywords Dry eye, Age, Ocular surface disease index score, Schirmer I test, Fluorescein break up time, Corneal fluorescence staining score

*Correspondence:

Minghong Gao
gaominghong88@yeah.net

¹Department of ophthalmology, the General Hospital of Northern Theater
Command, No.83, Wenhua Road, Shenhe District, 110840 Shenyang,
China



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Dry eye is now considered as an ocular surface disease characterized by loss of homeostasis in the tear film, accompanied by ocular symptoms, tear film instability and hyperosmolarity, inflammation and damage to the ocular surface [1]. The maintenance of the normal state of the ocular surface is inseparable from the coordinated regulation of various parts of the ocular surface tissue, thereby maintaining a healthy state of tears and tear film. Any damage to any link will affect the integrity of the tear film, and even affect its function, leading to the appearance of dry eye [2, 3].

Several approaches including ocular surface disease index (OSDI) score, Schirmer I test (SIT), fluorescein break up time (FBUT) and corneal fluorescence staining (FLCS) score [2, 4]. Studies have shown that dry eye is an age-related degenerative disease that is expected to cause an increasing public health burden worldwide as the population ages [5–7]. However, the changes in symptoms and signs of dry eye patients of different ages before and after treatment and whether there are differences need to be reported by more studies [8]. The Tear Film and Ocular Surface Society (TFOS) Dry Eye Workshop II (DEWS II) Epidemiological Report provides evidence of gender differences in the signs of dry eye with age, but results are variable and systematic stratified studies are advocated [5]. Therefore in this study, patients were divided into three groups according to age, and we aimed to compare the OSDI score, SIT, FBUT and FLCS score of dry eye patients at different ages before and after treatment.

Methods

Patients

A total of 90 eyes of 90 patients with mild to moderate dry eye who visited our outpatient clinic from September 2020 to September 2021 were retrospectively included. All patients provided written informed consent, and this study protocol was performed in accordance with the Declaration of Helsinki reviewed and was approved by the Ethics Committee of General Hospital of Northern Theater Command (2022-027). All patients had completed fundus examinations and slit lamp examinations to exclude other ocular surface diseases and fundus diseases except dry eye.

Inclusion criteria were patients (1) with symptoms including blurred vision, dry eyes, and foreign body sensation, which can be diagnosed as mild to moderate dry eye; (2) with no other dry eye related treatment has been received within 1 month; and (3) aged from 18 to 78 years, and do not suffer from mental and psychological diseases. Exclusion criteria were patients (1) with other ophthalmic diseases who need local or systemic use of other drugs that may affect the secretion of tears; (2) who had previous chemical burns, eye surgery, or

contact lenses; (3) with eyelid insufficiency, conjunctival sac relaxation, ectropion, or blepharospasm that affect the normal metabolism of drugs; (4) who were pregnant and lactating women or those who were taking hormone-related drugs; (6) those with immune-related diseases such as Sjögren's syndrome, Stevens-Johnson syndrome, abnormal thyroid function, and other serious diseases such as tumor diseases.

One eye of each patient was selected for the study, and if both eyes of the patient met the inclusion criteria, the right eye was selected as the study eye. The patients were divided into three groups according to age. Patients in young group were 20–39 years old, with a total of 29 cases and 29 eyes; Patients in middle-age group were 40–59 years old, with a total of 30 cases and 30 eyes; Patients in elder group were aged 60 years and above, with a total of 31 cases and 31 eyes. All patients were examined by the same ophthalmologist to complete their OSDI score, SIT, FBUT and corneal FLCS score at day 0.

Therapeutic method

All patients were given meibomian gland massage once a week for 4 times in a row by the same ophthalmic nurse. The therapeutic method was reported previously [9].

In addition, patients in each group were given polyethylene glycol eye drops (Siran, Alcon Laboratories, Inc) and vitamin A palmitate ophthalmic gel (Ziyang, Shenyang Xingqi Pharmaceutical Co., Ltd.) 3 times a day for 28 days. After each massage, levofloxacin eye drops (Colobito, Santian Pharmaceutical Co., Ltd.) were applied to the affected eye 3 times a day and gatifloxacin Ophthalmic gel (Diyu, Shenyang Xingqi Ophthalmic Co., Ltd.) was applied to the affected eye once a night. These two drugs were discontinued after continuous use for 3 days. Eye drops were performed by the same physician according to the standard procedure. Patients were followed up 7 days, 14 days and 28 days after treatment.

Observational index

All patients were examined by the same ophthalmologist to complete their OSDI score, SIT, FBUT and corneal FLCS score. The OSDI score include the scores of all 12 completed questions, ranging from 0 to 100 [10]. For SIT, take a 5 mm×35 mm standard filter paper strip (Tianjin Jingming New Technology Development Co., Ltd.), one end is folded for 5 mm, and the other end hangs down naturally and was inserted it into the junction of the middle and outer 1/3 of the lower eyelid. The filter paper was removed after 5 min, and the wetted length of the filter paper at the folded position < 10 mm can indicate the dry eye [11].

For FBUT, after soaked with chloramphenicol eye drops (Changchun Dirui Pharmaceutical Co., Ltd.), the fluorescein test strip (Tianjin Jingming New Technology

Table 1 Basic information

Variables	Young group (n=29)	Middle-age group (n=30)	Elder group (n=31)	P value
Male, n(%)	14(48.28)	14(46.67)	16(51.61)	0.925
Dry eye duration (month) (means ± SD)	4.37 ± 2.73	4.28 ± 2.30	4.56 ± 2.80	0.912
Diabetes history, n(%)	5(17.24)	8(26.67)	7(22.58)	0.683
Smoking history, n(%)	8(27.59)	6(20)	6(19.35)	0.783
OSDI score (means ± SD)	26.00 ± 5.47	26.10 ± 5.55	25.84 ± 5.24	0.979
SIT (mm/5min) (means ± SD)	4.59 ± 1.24	4.50 ± 1.17	4.42 ± 1.29	0.872
FBUT (s) (means ± SD)	4.31 ± 1.34	4.13 ± 1.55	4.00 ± 1.39	0.682
FLCS score (means ± SD)	3.10 ± 1.94	3.23 ± 1.87	3.45 ± 1.71	0.794

OSDI, ocular surface disease index; SIT, Schirmer I test; FBUT, fluorescein break up time; FLCS, corneal fluorescence staining

Development Co., Ltd.) was then applied to the patient's lower eyelid conjunctival sac. The patient blinked several times and stared forward, the cobalt blue light of the slit lamp microscope was selected for observation, and the stopwatch was used for measurement. The time from the patient opened his eyes after the last blink until the first randomly distributed dry spot on the cornea occurred was recorded for 3 consecutive times. An average time is less than 10s can indicate the dry eye [11].

For FLCS, a drop of chloramphenicol eye drops was used to infiltrate the tip of the fluorescein test strip and the strip was then placed in 1/3 of the patient's lower eyelid conjunctival sac. After blinking 3–4 times, the cornea was observed under the cobalt blue light of the slit lamp to see if the cornea was stained, and the score was 12 points: the cornea is divided into 4 quadrants, with each quadrant of 0–3 points; 0 points for no staining, 1 point for 1–5 punctate staining, 2 points for 5–30 spotty staining but unfused staining, and 3 points for corneal punctate staining fusion, filaments, and ulcers [12].

Statistical analysis

Statistical analysis was performed using SPSS version 23.0 (IBM Corp.). Values are presented as the mean ± standard deviation or numbers (percentage). One-way analysis of variance (ANOVA) was used for multiple continuous variables and the chi-square test was used to compare categorical data among the groups. Significance in OSDI score, SIT, FBUT and FLCS score were tested with two-way ANOVA followed by Bonferroni test. $P < 0.05$ was considered to indicate a statistically significant difference.

Results

There were no significant differences in gender, dry eye duration, diabetes history, smoking history, OSDI score, SIT, FBUT and FLCS score before treatment among the three groups ($P > 0.05$) (Table 1).

As shown in Table 2, OSDI score was not statistically different among the groups ($F = 3.22$, $P = 0.06$), and a significant time effect was found ($F = 427.21$, $P < 0.001$). There was also a significant interaction between time and groups ($F = 7.01$, $P < 0.001$). Regarding within-group differences, there were statistically significant differences between the three groups at each time point before and after treatment (all $P < 0.001$).

SIT was statistically different among the three groups ($F = 350.61$, $P < 0.001$), and a significant time effect was also found ($F = 80.87$, $P < 0.001$). There was a significant interaction between time and groups ($F = 10.70$, $P < 0.001$). SIT at 14 and 28 days after treatment in both middle-age group and elder group were lower than young group (all $P < 0.001$). SIT at 7, 14 and 28 days after treatment in elder group were lower than middle-age group (all $P < 0.001$). Regarding within-group differences, there were statistically significant differences between the three groups at each time point before and after treatment (all $P < 0.001$) (Table 3).

As shown in Table 4, FBUT was not statistically different among the groups ($F = 2.66$, $P = 0.08$), and a significant time effect was found ($F = 56.63$, $P < 0.001$). There was also a significant interaction between time and groups ($F = 4.58$, $P < 0.001$). No significant differences in FBUT at

Table 2 OSDI score among three groups

Variables (means ± SD)	Young group (n=29)	Middle-age group (n=30)	Elder group (n=31)	Mixed ANOVA (P value)		
				Group effect	Time effect	Interaction effect
Before treatment	26.07 ± 5.47	26.10 ± 5.55	25.84 ± 5.24	0.057	< 0.001	< 0.001
7 days after treatment	23.31 ± 4.98*	20.30 ± 4.47*	21.32 ± 4.20*			
14 days after treatment	19.10 ± 4.14*#	15.97 ± 3.82*#	17.74 ± 3.68*#			
28 days after treatment	14.97 ± 3.91*#&	10.67 ± 2.92*#&	13.26 ± 3.74*#&			

OSDI, ocular surface disease index

* $P < 0.05$, compared with OSDI score before treatment

$P < 0.05$, compared with OSDI score 7 days after treatment

& $P < 0.05$, compared with OSDI score 14 days after treatment

Table 3 SIT among three groups

Variables (means ± SD)	Young group (n = 29)	Middle-age group (n = 30)	Elder group (n = 31)	Mixed ANONA (P value)		
				Group effect	Time effect	Interaction effect
Before treatment	4.59 ± 1.24	4.50 ± 1.17	4.42 ± 1.29	< 0.001	< 0.001	< 0.001
7 days after treatment	6.55 ± 1.40*	6.10 ± 1.52*	5.10 ± 1.51 ^{ab*}			
14 days after treatment	8.41 ± 1.94 [#]	7.40 ± 1.83 ^{a*#}	6.23 ± 1.56 ^{ab*#}			
28 days after treatment	9.72 ± 1.77 ^{*#&}	8.10 ± 1.45 ^{a*#&}	6.97 ± 1.45 ^{ab*#&}			

SIT, Schirmer I test

*P < 0.05, compared with SIT before treatment

#P < 0.05, compared with SIT 7 days after treatment

&P < 0.05, compared with SIT 14 days after treatment

^aP < 0.05, compared with young group^bP < 0.05, compared with middle-age group**Table 4** FUBT among three groups

Variables (means ± SD)	Young group (n = 29)	Middle-age group (n = 30)	Elder group (n = 31)	Mixed ANONA (P value)		
				Group effect	Time effect	Interaction effect
Before treatment	4.31 ± 1.34	4.13 ± 1.55	4.00 ± 1.39	0.076	< 0.001	< 0.001
7 days after treatment	5.21 ± 1.61*	4.83 ± 1.68*	4.42 ± 2.01*			
14 days after treatment	5.86 ± 1.87 [#]	5.33 ± 1.69 [#]	5.00 ± 1.93 [#]			
28 days after treatment	6.93 ± 1.83 ^{*#&}	5.73 ± 2.02 [#]	5.13 ± 1.98 [#]			

FUBT, fluorescein break up time

*P < 0.05, compared with FUBT before treatment

#P < 0.05, compared with FUBT 7 days after treatment

&P < 0.05, compared with FUBT 14 days after treatment

Table 5 FLCS score among three groups

Variables (means ± SD)	Young group (n = 29)	Middle-age group (n = 30)	Elder group (n = 31)	Mixed ANONA (P value)		
				Group effect	Time effect	Interaction effect
Before treatment	3.1 ± 1.94	3.23 ± 1.87	3.45 ± 1.71	0.299	< 0.001	0.170
7 days after treatment	2.76 ± 1.90	3.07 ± 1.43	3.13 ± 1.78*			
14 days after treatment	2.41 ± 1.78*	2.73 ± 1.78 [#]	2.94 ± 1.71*			
28 days after treatment	1.10 ± 0.82 ^{*#&}	1.70 ± 1.32 ^{*#&}	2.32 ± 1.50 ^{*#&}			

FLCS, corneal fluorescence staining

*P < 0.05, compared with FLCS score before treatment

#P < 0.05, compared with FLCS score 7 days after treatment

&P < 0.05, compared with FLCS score 14 days after treatment

28 days after treatment were found compared with FUBT at 14 days after treatment in both middle-age group and elder group. In addition, there were statistically significant differences between the three groups at other time point before and after treatment (all $P < 0.001$).

As shown in Table 5, FLCS score was not statistically different among the groups ($F = 1.23$, $P = 0.30$), and a significant time effect was found ($F = 49.625$, $P < 0.001$). There was no significant interaction between time and groups ($F = 1.533$, $P = 0.170$). Regarding within-group differences, FLCS score was lower at 28 days after treatment than that before treatment and 7 and 14 days after treatment (all $P < 0.001$).

Discussion

According to recent epidemiological studies, the prevalence of dry eye has increased significantly, and there is a positive correlation between increasing age and clinical signs, clinical markers of dry eye, aqueous tear deficiency, and meibomian gland dysfunction [13, 14]. Therefore, dry eye is considered a multifactorial, age-related degenerative disease that progresses with cumulative lifetime exposure to multiple environmental and physiological factors, leading to hormonal modulation, neurosensory pathways, ocular changes in inflammation and tear film homeostasis [15, 16]. As the number of elderly people will continue to increase in the future, and the life expectancy of human beings will continue to increase, which will lead to the larger proportion of patients with dry eyes. Therefore, we need to further understand the

age-related dry eye in detail, so as to improve the status quo and guide treatment [17].

OSDI scores, SIT, FBUT, and FLCS scores of the OSDI scores in three groups at 28 days after treatment were significantly improved compared with those before treatment and 7 days after treatment, suggesting that long term treatment of dry eyes provides better results.

There were statistically significant differences between the three groups at each time point before and after treatment. Overall, though not significantly different, the OSDI scores of middle-age group at each time point were lower than the other two groups, considering that the cumulative exposure due to advances in science and technology and lifestyle factors may vary by age group [18]. In addition, ocular nerve sensitivity and response sensitivity decreases with increasing age.

SIT is the most direct way to detect tear secretion, and the increase of tear secretion can directly improve the symptoms of ocular surface discomfort and visual quality of patients. SIT at 7, 14 and 28 days after treatment in elder group were lower than middle-age group in this study. The recovery of tear deficiency is more pronounced and faster in patients under 60 years of age than in those over 60 years of age [18]. We believe that the reason is that sex hormone levels may regulate tear production through their effects on the ocular surface to stabilize the ocular surface environment, and with age, hormone levels gradually decline, affecting tear production to a certain extent [19, 20]. Hormone replacement therapy appears to have a beneficial effect on lacrimal secretion, based on evaluation of the tear secretion test, and this effect is age-related [21]. With regard to age-based differences in the clinical efficacy of dry eye, in the case of SIT, tear secretory glands and their neural connections comprise tear functional units, and abnormalities in some of these units can lead to dysfunction. The normal lacrimal gland is composed of 80% acinar cells, which store and secrete tear components. An animal study found that age causes progressive changes in lacrimal acinar cells, and the type of acinar changes from initially serous to serous-mucinous acinus, and then gradually to mucinous acinus [22]. In addition, with increasing age, the lacrimal gland develops excessive structural damage, mast cell infiltration, periductal fibrosis, acinar atrophy, and chronic inflammation. The ability of the acini to synthesize and secrete proteins gradually decreased or disappeared in mice aged 3 months to 5 months to 20 months to 24 months [23]. These morphological and secretory changes also explain the decrease in tear secretion with age.

FBUT is a method for evaluating the stability of the tear film of patients, which is reproducible, less irritating to the patient, and the results are objective and accurate. Therefore, it is widely used in clinical practice. In this study, the FBUT measurement of all patients was

completed by the same physician in the same environment, which eliminated the influence of external factors such as the size of the eye cleft, the environmental humidity, and the dose of fluorescein staining. Though not significantly different, FBUT at 28 days after treatment of young group were higher than the other two groups. The optimal prognostic cut-off age for tear film instability and hyperosmolarity may occur in the 40th year of life, between 33 and 38 years old. In elderly patients with dry eye, high osmotic pressure may have an association between and lower FBUT [18], and the recovery of tear film stability is more pronounced and faster in patients under 40 years of age than in those over 40 years.

Corneal FLCS is a commonly used clinical method for evaluating corneal damage. Corneal and conjunctival staining of the ocular surface is considered to be a sign of a more severe stage in the later development of dry eye [14, 18, 24], indicating compromised corneal, conjunctival, and lid margin epithelial integrity [25, 26]. FLCS at 28 days after treatment in three groups were significantly lower than other time points. Changes in tear film homeostasis in dry eyes may increase the drying risk due to tear film instability and excessive evaporation through an inflammatory cascade triggered by tear film hyperosmolarity, resulting in damage to the ocular surface epithelium and blinking with reduced lubrication and increased friction [16, 27, 28], the delayed onset of this injury therefore requires long-term treatment [29].

The sample size and short follow-up time were limitations of this study. In addition, this study is lack of relevant biochemical indicators. The lack of significant difference in baseline OSDI among different groups is also a limitation to the study. Blepharitis in patients were not assessed and studied as a possible co-founding variable in this study. A higher prevalence of dry eye in females were not shown in our study, which may be due to the small sample size. Therefore, large-scale and long-term researches remain to be done in the future. During the study period, all patients in three age groups wore masks due to the 2019 novel coronavirus (COVID-19). However "Mask associated dry eye (MADE)", as a known entity, was not discussed in detail.

Conclusion

Dry eye patients are given a 28-day topical lubricating ocular surface and repair-promoting drugs combined with local physical therapy, which can relieve symptoms, promote tear secretion, improve tear film stability, and promote the recovery of corneal and ocular surface integrity. As a long-term, chronic ocular surface disease, durable treatment is required. Age affects the treatment effect of patients with mild to moderate dry eye, among which the tear secretion is the most significant. Treatment of

dry eye should be detected and managed early on to protect the ocular surface.

Abbreviations

OSDI	Ocular surface disease index
SIT	Schirmer I test
FBUT	Fluorescein break up time
FLCS	Fluorescence staining
TFOS	Tear Film and Ocular Surface Society
DEWS II	Dry Eye Workshop II
ANOVA	Analysis of variance

Acknowledgements

None.

Authors' contributions

Conception and design, Y Chen and M Gao; Administrative support, Y Chen; Provision of study materials or patients, Y Wu; Collection and assembly of data, Y Wu, K Zhang and R Gao; Data analysis and interpretation, M Gao, Y Chen and Y Wu; All the authors have read and approved the final manuscript.

Funding

Not applicable.

Data Availability

All data generated or analyzed during this study are included in this article.

Declarations

Ethics approval and consent to participate

All patients provided written informed consent, and this study protocol was performed in accordance with the Declaration of Helsinki reviewed and was approved by the Ethics Committee of General Hospital of Northern Theater Command (2022-027).

Consent for publication

Not applicable.

Competing interests

All authors declare that they have no conflict of interest.

Received: 27 May 2022 / Accepted: 20 September 2022

Published online: 05 October 2022

References

- Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, Liu Z, Nelson JD, Nichols JJ, Tsubota K, et al. TFOS DEWS II Definition and Classification Report. *Ocul Surf*. 2017;15(3):276–83.
- Willcox MDP, Argüeso P, Georgiev GA, Holopainen JM, Laurie GW, Millar TJ, Papas EB, Rolland JP, Schmidt TA, Stahl U, et al. TFOS DEWS II Tear Film Report. *Ocul Surf*. 2017;15(3):366–403.
- Chuang J, Shih KC, Chan TC, Wan KH, Jhanji V, Tong L. Preoperative optimization of ocular surface disease before cataract surgery. *J Cataract Refract Surg*. 2017;43(12):1596–607.
- Chapter ADEAC. Expert consensus on dry eye in China: definition and classification. *Chin J Ophthalmol*. 2020;56(6):418–22.
- Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, Na KS, Schaumberg D, Uchino M, Vehof J, et al. TFOS DEWS II Epidemiology Report. *Ocul Surf*. 2017;15(3):334–65.
- Kawashima M. Systemic Health and Dry Eye. *Investig Ophthalmol Vis Sci*. 2018;59(14):Des138–des142.
- Farrand KF, Fridman M, Stillman I, Schaumberg DA. Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older. *Am J Ophthalmol*. 2017;182:90–8.
- Ding J, Sullivan DA. Aging and dry eye disease. *Exp Gerontol*. 2012;47(7):483–90.
- Liu Z. Expert consensus on dry eye in China: treatment. *Chinese Journal of Ophthalmology*, 56(12):7.
- Zheng B, Liu XJ, Sun YF, Su JZ, Zhao Y, Xie Z, Yu GY. Development and validation of the Chinese version of dry eye related quality of life scale. *Health Qual Life Outcomes*. 2017;15(1):145.
- Chapter ADEAC. Expert consensus on dry eye in China: examination and diagnosis. *Chin J Ophthalmol*. 2020;56(10):714–47.
- Zhang Y, Yi G, Ke X, Li S, Zhang Z, Chen X. Effects of Demodex mites on ocular surface function in patients with Meibomian gland dysfunction. *Int J Ophthalmol*. 2019;19(7):4.
- Rico-Del-Viejo L, Lorente-Velázquez A, Hernández-Verdejo JL, García-Mata R, Benítez-Del-Castillo JM, Madrid-Costa D. The effect of ageing on the ocular surface parameters. Contact lens & anterior eye: the journal of the British Contact Lens Association. 2018;41(1):5–12.
- Wang MTM, Craig JP. Natural history of dry eye disease: Perspectives from inter-ethnic comparison studies. *Ocul Surf*. 2019;17(3):424–33.
- Knop E, Knop N, Millar T, Obata H, Sullivan DA: The international workshop on meibomian gland dysfunction: Report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. *Investigative ophthalmology & visual science* 2011, 52(4):1938–1978.
- Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, Knop E, Markoulli M, Ogawa Y, Perez V, et al. TFOS DEWS II pathophysiology report. *Ocul Surf*. 2017;15(3):438–510.
- Pflugfelder SC. Prevalence, burden, and pharmacoconomics of dry eye disease. *Am J Manag Care*. 2008;14(3 Suppl):102–6.
- Wang MTM, Muntz A, Lim J, Kim JS, Lacerda L, Arora A, Craig JP. Ageing and the natural history of dry eye disease: A prospective registry-based cross-sectional study. *Ocul Surf*. 2020;18(4):736–41.
- Wickham LA, Gao J, Toda I, Rocha EM, Ono M, Sullivan DA. Identification of androgen, estrogen and progesterone receptor mRNAs in the eye. *Acta Ophthalmol Scand*. 2000;78(2):146–53.
- Gupta PD, Johar K, Sr., Nagpal K, Vasavada AR. Sex hormone receptors in the human eye. *Surv Ophthalmol*. 2005;50(3):274–84.
- Feng Y, Feng G, Peng S, Li H. The effects of hormone replacement therapy on dry eye syndromes evaluated by Schirmer test depend on patient age. *Contact lens & anterior eye: the journal of the British Contact Lens Association*. 2016;39(2):124–7.
- Vais VB, Vangeli IM, Bakeeva LE. Ultrastructural changes in ageing lacrimal gland in Wistar rats. *Bull Exp Biol Med*. 2014;157(2):268–72.
- Li J, Ma J, Hu M, Yu J, Zhao Y. Assessment of tear film lipid layer thickness in patients with Meibomian gland dysfunction at different ages. *BMC Ophthalmol*. 2020;20(1):394.
- Wang MTM, Dean SJ, Xue AL, Craig JP. Comparative performance of lid wiper epitheliopathy and corneal staining in detecting dry eye disease. *Clin Exp Ophthalmol*. 2019;47(4):546–8.
- Uchino M, Dogru M, Yagi Y, Goto E, Tomita M, Kon T, Saiki M, Matsumoto Y, Uchino Y, Yokoi N. The features of dry eye disease in a Japanese elderly population. *Optom Vis Sci*. 2006;83(11):797–802.
- Mathers WD, Lane JA, Zimmerman MB. Tear film changes associated with normal aging. *Cornea*. 1996;15(3):229–34.
- Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. *Cornea*. 2011;30(4):379–87.
- Korb DR, Herman JP, Blackie CA, Scaffidi RC, Greiner JV, Exford JM, Finnemore VM. Prevalence of lid wiper epitheliopathy in subjects with dry eye signs and symptoms. *Cornea*. 2010;29(4):377–83.
- Craig JP, Muntz A, Wang MTM, Luensmann D, Tan J, Trave Huarte S, Xue AL, Jones L, Willcox MDP, Wolffsohn JS. Developing evidence-based guidance for the treatment of dry eye disease with artificial tear supplements: A six-month multicentre, double-masked randomised controlled trial. *Ocul Surf*. 2021;20:62–9.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

onlineservice@springernature.com